The 5-HT1A agonism is a feature of multiple pharmacotherapies, including aripiprizole, vilazadone and buspirone for schizophrenia, depression and anxiety disorders, respectively, suggesting complex and diverse behavioral effects resulting from the activation of this receptor.19, 20, 48, 49. The gene discussed is HTR1A; the disease is depressive symptom measurement.